Clinical trials: Refractory Ascites
Cirrhosis, Liver, Refractory Ascites
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
This is a single centre, prospective, uncontrolled study to include 12 consecutive patients with cirrhosis of the liver and recurrent or refractory ascites.
- Trial name
- NCT01438970
- Testing
- ALFApump system
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Sequana Medical N.V.
Liver Cirrhosis, Ascites
Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis
Ascites is the most frequent complication of liver cirrhosis and carries a significant worsening of the prognosis. Approximately 10% of patients per year develop refractory ascites because of either the lack of response to…
- Trial name
- ANSWER (NCT01288794)
- Testing
- Diuretics plus human albumin, Diuretics (standard medical treatment)
- Where
- 33 sites in Italy
- Volunteers
- 431 people
- Sponsor
- University of Bologna
Immune Function in Blood, Liver Function in Blood
Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites
Liver cirrhosis (LC) is the final destiny in chronic liver disease.The quality of life in liver cirrhosis patients with refractory ascites are very wretched.
- Conditions
- Immune Function in Blood, Liver Function in Blood, Variation of Ascites, Characters of Quality of Life
- Trial name
- NCT01854125
- Testing
- autologous bone marrow mesenchymal stem cells transplantation, autologous bone marrow msenchymal stem cells transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing PLA General Hospital
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Cirrhosis, Liver, Liver Fibrosis
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2).
- Conditions
- Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
- Trial name
- NCT05490888
- Testing
- PHIN-214 Subcutaneous injection
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- PharmaIN
Ascites Hepatic
Empagliflozin as a Novel Therapy in Refractory Ascites
The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients…
- Trial name
- NCT05430243
- Testing
- Empagliflozin 10 MG, Diuretics
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Alexandria University
Cirrhosis, Liver, Acute-On-Chronic Liver Failure
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF…
- Conditions
- Cirrhosis, Liver, Acute-On-Chronic Liver Failure, Refractory Ascites, Ascites
- Trial name
- NCT05700708
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cirrhosis, Ascites Hepatic
Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
- Trial name
- NCT03107091
- Testing
- Terlipressin acetate continuous infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- BioVie Inc.
Malignant Ascites, Apatinib
A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
Malignant ascites is a severe complication of many types of human cancer. Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant ascites.
- Trial name
- NCT03020979
- Testing
- Apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Liver Cirrhosis, Refractory Ascites
ALFApump System Post Marketing Surveillance Registry
This is a post market surveillance registry to monitor the safety and performance of the ALFApump system.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Malignant Ascites
- Trial name
- 2011-AAR-004 (NCT01532427)
- Where
- 13 sites in Germany, Spain and 2 more
- Volunteers
- 100 people
- Sponsor
- Sequana Medical N.V.
Hepatic Encephalopathy, Cirrhosis, Liver
HepQuant to Predict Hepatic Encephalopathy After TIPS
A pilot study to determine if a simple blood test can predict patients at risk for significant episodes of confusion and disorientation that can occur in patients who receive an artificial shunt through the liver to control…
- Trial name
- NCT04664621
- Testing
- HepQuant
- Where
- United States
- Sponsor
- Northwestern University
Liver Cirrhoses
Early Use of TIPS With Polytetrafluoroethylene(PTFE) Covered Stents in Cirrhotic Patients With Refractory Ascites
This multicenter RCT is designed to investigate if TIPS with covered stents improves transplant-free survival for cirrhotic patients with early stage of refractory ascites compared to LVP+albumin during 1 year follow-up period.
- Trial name
- NCT03172273
- Testing
- TIPS, paracentesis
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Air Force Military Medical University, China
Ascites, Liver Cirrhosis
North American Study for the Treatment of Refractory Ascites (NASTRA)
The NASTRA Clinical Trial is a multi-center, randomized, controlled clinical trial designed to determine if treatment with transjugular intrahepatic portasystemic shunts (TIPS) is superior to high volume paracentesis (total…
- Trial name
- NCT00006166
- Testing
- Transjugular intrahepatic portasystemic shunts (TIPS), Total paracentecis (TP)
- Where
- 6 sites in United States, Canada
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Refractory Malignant Ascites
Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology
Malignant ascites leads to significant morbidity in patients with terminal cancer. Paracentesis can provide relief, but repeat hospital visits, pain, and short duration of relief after paracentesis are detrimental to quality of…
- Trial name
- NCT02477657
- Testing
- Paracentesis, Tunneled Intraperitoneal Drain (IPD), Peritoneal-Venous shunts (PVS)
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Ascites
High Dose Albumin in Refractory Ascites
Advanced cirrhosis with complications is a serious problem imposing a heavy financial burden on health care system. Moreover, ascites is associated with increase in mortality rates among cirrhotic patients.
- Trial name
- NCT05867602
- Testing
- Albumin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Baylor College of Medicine
Cirrhosis, Refractory Ascites
Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy
This study will evaluate whether a nutritional intervention is better than another to reduce the incidence of overt hepatic encephalopathy in patients undergoing TIPS insertion for refractory ascites.
- Conditions
- Cirrhosis, Refractory Ascites, TIPS Insertion
- Trial name
- SUPPRESS-HE (NCT07634237)
- Testing
- High Energy and High Protein Diet 1, High Energy and High Protein Diet 2
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Hepatorenal Syndrome, Cirrhosis, Liver
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF…
- Conditions
- Hepatorenal Syndrome, Cirrhosis, Liver, Acute-On-Chronic Liver Failure, AKI
- Trial name
- NCT05434286
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 75 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Type 2 Hepatorenal Syndrome, Refractory Ascites
The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are mediated in part by diminished circulatory volume and that treatment with midodrine, octreotide and albumin can improve renal and patient…
- Trial name
- NCT00240045
- Testing
- Midodrine, albumin, octreotide LAR, midodrine, octreotide, albumin
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University of Alberta
Liver Diseases, Portal Hypertension
TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites
Transjugular intrahepatic portosystemic shunt (TIPS) could effectively decrease portal hypertension-related complications. This study intends to evaluate the efficacy and safety of TIPS combined with subsequent microwave ablation…
- Conditions
- Liver Diseases, Portal Hypertension, Cirrhosis, Liver, Ascites
- Trial name
- NCT04640116
- Testing
- Transjugular intrahepatic portosystemic shunt (TIPS), microwave ablation (MWA)
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University